Opportunities
Search

Expected Outcome:Project results are expected to contribute to all the following expected outcomes:Enhanced reliability, resilience, and efficiency of electricity transmission grids. Grid congestion is managed efficiently;Enhanced observability of grids and improved forecasting of supply, demand, grid capacity availability, and flexibility;Transmission system operators (TSO) leverage modern digital solutions and employ improved systems to effectively manage their grids and improve interoperability with other TSOs;Vendor-agnostic reference architectures, solutions and tools are developed to help advancing the TSO control room design and operation. Scope:Projects are expected to address all the following items:Design and test innovative solutions, technologies and processes for advancing the way the TSO control rooms are designed and operated, increasing observability and entailing enhance...

Expected Outcome:Large PV systems such as utility scale PV are evolving towards higher voltage architecture (>=3kV) with the objective to minimize losses and improve system efficiency at lower costs. The intention is to integrate also storage into such (hybrid) PV systems offering flexibility. It is consequently essential to build a blueprint for the implementation of high voltage large PV systems and the development of Direct Current (DC) networks around strategic end users for high voltage demand (industrial sites, servers, electric vehicle charging stations…). Understanding the factors that influence the performance and economics of these system architectures will help system planners evaluate the potential benefits of such hybrid resources that could support an increasing future industrial electrification. Another crucial challenge to address in ensuring the continued growth of new i...

Expected Outcome:Project results are expected to contribute to all the following expected outcomes:Enhanced reliability, resilience, controllability and efficiency of electricity distribution grids. Congestion in distribution grids is managed effectively;Distribution system operators (DSO) leverage modern digital solutions and employ improved systems to effectively manage their grids and improve interoperability with TSOs and other DSOs;Vendor-agnostic reference architectures, solutions and tools are developed to help advancing the ADSM design and operation and effectively manage a broad range of grid services. Scope:Projects are expected to address all the following items:Design and test innovative solutions, architectures, technologies and processes for advancing the way the ADSM are designed and operated;Provide ADSM software platforms that improve grid performance, controllability, a...

Expected Outcome:Project results are expected to contribute to all the following expected outcomes:Improved energy security of the energy system by offering cost-effective and efficient solutions for additional diverse and flexible energy storage capacities.Improve the sustainability and circularity of energy storage systems.Enhanced economic viability of energy storage by utilizing existing infrastructures. Scope:Demonstration of novel or improved technological solutions for cost-efficient, circular and sustainable energy storage, which contribute to grid flexibility and make use of existing obsolete or outdated energy or other infrastructures. Proposals should integrate the synergies between novel or improved energy storage technologies and retrofitting of obsolete or outdated infrastructures, like e.g. old hydropower dams and basins, decommissioned power plants, former industrial faci...

Expected Outcome:Project results are expected to contribute to all the following expected outcomes:Enhanced EU cooperation to generate knowledge sharing on data and analytics used for the planning and operation of European grids, and market integration;Better EU coordination with regard to planning and simulation tools to support the development of electricity grids and integration of RES are made available to the research, academia, grid operators, and key actors in the energy value chains;Coordinated processes to generate new and innovative open-source solutions, software modules etc. that are added to the existing and/or new repositories that support the development of grids and integration of high shares of RES;Improved EU-wide cooperation and coordination of actions on developing and utilising innovative data-driven solutions for energy, including AI-powered tools.Support to researc...

Expected Outcome:For a renewables-based electricity system sufficient flexible and also in the long-run fully sustainable hydropower capacity is pivotal.Project results are expected to contribute to all of the following expected outcomes:Enhancing the capacities of the hydropower fleet to contribute with variable renewables base load to a secure and stable electricity system, including by modernising grid integration and hydropower fleet control.Increase technology leadership, competitiveness and technology export potential of European hydropower industry.Address challenges of climate change adaptation for a forward-looking and stable operation of sustainable hydropower for the coming decades. Scope:Demonstration of hydropower technology solutions which allow for efficient and forward-looking refurbishment of existing hydropower plants. Provided solutions must be socioeconomically and en...

Expected Outcome:Project results are expected to contribute to all of the following outcomes: Near-to-market solutions for the safe integration and use of CCUS technologies in the energy- and carbon-intensive industry;A pipeline of projects that have the potential for commercial scale-up.Deeper understanding of the needs and concerns of diverse social groups involved in or potentially affected by the R&I development of the technology, thereby increasing the potential for beneficial societal uptake and building trust in results and outcomes. Scope:Projects are expected to be the de-risking first step to develop local or regional industrial CCUS clusters, i.e. (multi) source and (multi) sink solutions for the decarbonisation of the hard-to-abate industries of the region. Projects are expected to be the basis and orientation for future full-size projects. To maximise the impact, projects sh...

Expected Outcome:The REPowerEU plan and the EU Solar Energy Strategy introduced targets for the deployment of solar PV amounting to 600 GWac by 2030. Complying with these targets will be crucial for the European Union to reach its climate targets and free itself from import dependency on fossil fuels and the costs this imposes on Europe’s competitiveness in terms of high energy prices. The Solar Strategy also introduces a target, which has been enshrined into the Net-Zero Industry Act, to re-consolidate the European solar manufacturing sector and scale up European manufacturing capacity across the entire value chain to at least 40% of the EU’s annual deployment needs, or 30 GW of annual capacity by 2030. Innovation is particularly important in the solar PV sector, which is characterised by a short technology cycle, where new technologies become mainstream in only a few years. Novel tande...

The purpose of this Notice of Opportunity Announcement (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational supportneeded for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects. The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools. The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite...

The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this NOFO.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes. The goal of this NOFO is to support proof of concept studies for feasibility and exploratory development. Feasibility must not have already been developed in the literature or with preliminary data. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable. Investigators who have generated unpublished preliminary data should submit a proposal to companion R01.

The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.

This Notice of Funding Opportunity Announcement (NOFO) is designed to encourage and facilitate the entry of investigators to the area of brain imaging research. This NOFO will support both newly independent investigators and established investigators who are seeking to develop and adopt neuroimaging tools and methodologies in their research programs and conduct small "proof-of-concept" studies relevant to substance use disorders and addiction. This NOFO is intended to support Small Research Grant (R03) projects that can be carried out in a short period of time with limited resources.

This Notice of Funding Opportunity (NOFO) intends to support fundamental research that will contribute to basic understanding of skin injuries caused by chemicals that have been identified as public health threats, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for medical countermeasure development.

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Notice of Funding Opportunity (NOFO) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This NOFO is intended to support effectiveness trials testing post-acute phase interventions that are statistically powered to provide a definitive answer regarding the study intervention's effectiveness. Support for pilot effectiveness trials to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches is provided via a companion R34 (Currently TEMP-24814)

NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This Notice of Funding Opportunity (NOFO) supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 currently TEMP-24813.